Cargando…

The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study

Butyrate is a short-chain fatty acid that plays a key role in maintaining gut homeostasis as well as the integrity of the intestinal barrier. In the present study, we investigated the effect of oral microencapsulated sodium butyrate (BLM) administration in maintaining remission and improving residua...

Descripción completa

Detalles Bibliográficos
Autores principales: Vernero, Marta, De Blasio, Federico, Ribaldone, Davide Giuseppe, Bugianesi, Elisabetta, Pellicano, Rinaldo, Saracco, Giorgio Maria, Astegiano, Marco, Caviglia, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762036/
https://www.ncbi.nlm.nih.gov/pubmed/33291846
http://dx.doi.org/10.3390/jcm9123941
_version_ 1783627709068345344
author Vernero, Marta
De Blasio, Federico
Ribaldone, Davide Giuseppe
Bugianesi, Elisabetta
Pellicano, Rinaldo
Saracco, Giorgio Maria
Astegiano, Marco
Caviglia, Gian Paolo
author_facet Vernero, Marta
De Blasio, Federico
Ribaldone, Davide Giuseppe
Bugianesi, Elisabetta
Pellicano, Rinaldo
Saracco, Giorgio Maria
Astegiano, Marco
Caviglia, Gian Paolo
author_sort Vernero, Marta
collection PubMed
description Butyrate is a short-chain fatty acid that plays a key role in maintaining gut homeostasis as well as the integrity of the intestinal barrier. In the present study, we investigated the effect of oral microencapsulated sodium butyrate (BLM) administration in maintaining remission and improving residual symptoms and inflammatory markers in a population of patients with ulcerative colitis (UC). Forty-two patients with UC in clinical remission were enrolled in the study. Three patients were lost to follow up; 39 patients (18 treated with BLM add-on therapy and 21 with standard mesalamine only) that reached 12 months of follow up were included in the final analysis. Therapeutic success (defined as Mayo partial score ≤ 2 and faecal calprotectin (FC) < 250 µg/g at 12 months of follow up) was achieved in 25 patients (64.1%); 15/18 (83.3%) in BLM group and 10/21 (47.6%) in control group (p = 0.022). Consistently, 13/18 patients (72.2%) receiving BLM improved residual symptoms compared to 5/21 patients (23.8%) in control group (p = 0.003). FC values significantly diminished from the baseline to the end of follow up in patients that received BLM, while FC values remained almost stable in the control group. In conclusion, oral BLM supplementation appears to be a valid add-on therapy in order to maintain remission in patients with UC. Further randomized, placebo-controlled, double-blind clinical trials are needed to validate our results on a larger population or cohort of patients.
format Online
Article
Text
id pubmed-7762036
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77620362020-12-26 The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study Vernero, Marta De Blasio, Federico Ribaldone, Davide Giuseppe Bugianesi, Elisabetta Pellicano, Rinaldo Saracco, Giorgio Maria Astegiano, Marco Caviglia, Gian Paolo J Clin Med Article Butyrate is a short-chain fatty acid that plays a key role in maintaining gut homeostasis as well as the integrity of the intestinal barrier. In the present study, we investigated the effect of oral microencapsulated sodium butyrate (BLM) administration in maintaining remission and improving residual symptoms and inflammatory markers in a population of patients with ulcerative colitis (UC). Forty-two patients with UC in clinical remission were enrolled in the study. Three patients were lost to follow up; 39 patients (18 treated with BLM add-on therapy and 21 with standard mesalamine only) that reached 12 months of follow up were included in the final analysis. Therapeutic success (defined as Mayo partial score ≤ 2 and faecal calprotectin (FC) < 250 µg/g at 12 months of follow up) was achieved in 25 patients (64.1%); 15/18 (83.3%) in BLM group and 10/21 (47.6%) in control group (p = 0.022). Consistently, 13/18 patients (72.2%) receiving BLM improved residual symptoms compared to 5/21 patients (23.8%) in control group (p = 0.003). FC values significantly diminished from the baseline to the end of follow up in patients that received BLM, while FC values remained almost stable in the control group. In conclusion, oral BLM supplementation appears to be a valid add-on therapy in order to maintain remission in patients with UC. Further randomized, placebo-controlled, double-blind clinical trials are needed to validate our results on a larger population or cohort of patients. MDPI 2020-12-04 /pmc/articles/PMC7762036/ /pubmed/33291846 http://dx.doi.org/10.3390/jcm9123941 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vernero, Marta
De Blasio, Federico
Ribaldone, Davide Giuseppe
Bugianesi, Elisabetta
Pellicano, Rinaldo
Saracco, Giorgio Maria
Astegiano, Marco
Caviglia, Gian Paolo
The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
title The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
title_full The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
title_fullStr The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
title_full_unstemmed The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
title_short The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
title_sort usefulness of microencapsulated sodium butyrate add-on therapy in maintaining remission in patients with ulcerative colitis: a prospective observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762036/
https://www.ncbi.nlm.nih.gov/pubmed/33291846
http://dx.doi.org/10.3390/jcm9123941
work_keys_str_mv AT verneromarta theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT deblasiofederico theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT ribaldonedavidegiuseppe theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT bugianesielisabetta theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT pellicanorinaldo theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT saraccogiorgiomaria theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT astegianomarco theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT cavigliagianpaolo theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT verneromarta usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT deblasiofederico usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT ribaldonedavidegiuseppe usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT bugianesielisabetta usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT pellicanorinaldo usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT saraccogiorgiomaria usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT astegianomarco usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy
AT cavigliagianpaolo usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy